首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2422305篇
  免费   178670篇
  国内免费   3430篇
耳鼻咽喉   33337篇
儿科学   79469篇
妇产科学   65458篇
基础医学   358700篇
口腔科学   65600篇
临床医学   216699篇
内科学   470734篇
皮肤病学   54133篇
神经病学   191217篇
特种医学   91559篇
外国民族医学   520篇
外科学   366306篇
综合类   48596篇
现状与发展   12篇
一般理论   867篇
预防医学   186539篇
眼科学   56713篇
药学   180499篇
  10篇
中国医学   4800篇
肿瘤学   132637篇
  2021年   19298篇
  2019年   19869篇
  2018年   27556篇
  2017年   20757篇
  2016年   23397篇
  2015年   26394篇
  2014年   37110篇
  2013年   55445篇
  2012年   76583篇
  2011年   81349篇
  2010年   48311篇
  2009年   45749篇
  2008年   76602篇
  2007年   81627篇
  2006年   82547篇
  2005年   80151篇
  2004年   76738篇
  2003年   73932篇
  2002年   71642篇
  2001年   112940篇
  2000年   115607篇
  1999年   97084篇
  1998年   28087篇
  1997年   24718篇
  1996年   24921篇
  1995年   23511篇
  1994年   21605篇
  1993年   20453篇
  1992年   74455篇
  1991年   72532篇
  1990年   70820篇
  1989年   68013篇
  1988年   62398篇
  1987年   61107篇
  1986年   57173篇
  1985年   54888篇
  1984年   40709篇
  1983年   34518篇
  1982年   20549篇
  1979年   37263篇
  1978年   26685篇
  1977年   22094篇
  1976年   21099篇
  1975年   22770篇
  1974年   27126篇
  1973年   25747篇
  1972年   24038篇
  1971年   22835篇
  1970年   20993篇
  1969年   19944篇
排序方式: 共有10000条查询结果,搜索用时 703 毫秒
11.
12.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
13.
14.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
15.
16.
17.
BackgroundTotal hip and knee arthroplasties are increasingly performed operations, and routine follow-up places huge demands on orthopedic services. This study investigates the effectiveness, patients’ satisfaction, and cost reduction of Virtual Joint Replacement Clinic (VJRC) follow-up of total hip arthroplasty and total knee arthroplasty patients in a university hospital. VJRC is especially valuable when in-person appointments are not advised or feasible such as during the COVID-19 pandemic.MethodsA total of 1749 patients who were invited for VJRC follow-up for knee or hip arthroplasty from January 2017 to December 2018 were included in this retrospective study. Patients were referred to VJRC after their 6-week postoperative review. Routine VJRC postoperative review was undertaken at 1 and 7 years and then 3-yearly thereafter. We evaluated the VJRC patient response rate, acceptability, and outcome. Patient satisfaction was measured in a subgroup of patients using a satisfaction survey. VJRC costs were calculated compared to face-to-face follow-up.ResultsThe VJRC had a 92.05% overall response rate. Only 7.22% required further in-person appointments with only 3% being reviewed by an orthopedic consultant. VJRC resulted in an estimated saving of £42,644 per year at our institution. The patients’ satisfaction survey showed that 89.29% of the patients were either satisfied or very satisfied with VJRC follow-up.ConclusionVJRC follow-up for hip and knee arthroplasty patients is an effective alternative to in-person clinic assessment which is accepted by patients, has high patient satisfaction, and can reduce the cost to both health services and patients.  相似文献   
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号